Darah Cummins
Family · Eldorado, ILNPI 1962174409
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $893 of the $1,002 with a category attached, or 89.1%. 10 manufacturers reported payments, led by ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) at 35.7% of the total. 2025 is the largest year on record at $927, more than ten times the $37 reported in 2022.
Across 45 payments — averaging $22.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$357
- Vanda Pharmaceuticals Inc.$178
- Teva Pharmaceuticals USA, Inc.$151
- AbbVie$97
- Alkermes, Inc.$86
- Axsome Therapeutics, Inc.$47
- plus $86 from 4 others
What the payments were for
- Food & beverage$89389%
- Education$10911%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 19 | $357 |
| Vanda Pharmaceuticals Inc. | 6 | $178 |
| Teva Pharmaceuticals USA, Inc. | 4 | $151 |
| AbbVie | 5 | $97 |
| Alkermes, Inc. | 4 | $86 |
| Axsome Therapeutics, Inc. | 2 | $47 |
| Otsuka America Pharmaceutical, Inc. | 2 | $28 |
| Idorsia Pharmaceuticals US Inc | 1 | $24 |
| Exact Sciences | 1 | $19 |
| Johnson & Johnson | 1 | $16 |
How this compares
$1,002 in reported general payments places this provider in the 70th percentile of 4,941 family providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Paliperidone ErPaliperidone | 13 | $982 |
| Ziprasidone Hcl | 18 | $427 |
| Olanzapine | 20 | $298 |
| Divalproex Sodium ErDivalproex Sodium | 18 | $234 |
| Risperidone | 16 | $170 |
| Aripiprazole | 11 | $133 |
| Alprazolam | 23 | $111 |
| Bupropion XlBupropion Hcl | 21 | $110 |
| Prazosin Hcl | 16 | $93 |
| Clonazepam | 20 | $57 |
| Azithromycin | 13 | $55 |
| Lisinopril | 11 | $32 |
Paid to pharmacies, not to this prescriber.
Other family in Eldorado
- Ruth CarricoChicago$578K
- Aleksandra BielawiecBarrington$373K
- Erin SieberNaperville$334K
- Jamie BroganChicago$282K
- Ashley NoethGlen Carbon$271K
- Marita KametasChicago$259K
- Shammona ClarkChicago$247K
- Amanda McKeeMount Vernon$242K
- Amy BrownellElk Grove Village$202K
- Brittony CroasdellChicago$192K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.